Titre :

ZUMA-23 : a global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma

Auteur(s) :

Westin, J. [Auteur]
MD Anderson Cancer Center [Houston]
Jacobson, C. A. [Auteur]
Dana-Farber Cancer Institute [Boston]
Chavez, J. C. [Auteur]
H. Lee Moffitt Cancer Center and Research Institute
Sureda, A. [Auteur]
Morschhauser, Franck [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Glaß, B. [Auteur]
Helios Klinikum [Erfurt]
Dickinson, M. [Auteur]
Peter MacCallum Cancer Centre
Davies, A. [Auteur]
University of Southampton
Flinn, I. W. [Auteur]
Sarah Cannon Research Institute [Nashville, Tennessee]
Maloney, D. G. [Auteur]
Fred Hutchinson Cancer Research Center [Seattle] [FHCRC]
Chamuleau, M. [Auteur]
Amsterdam University Medical Centers [Amsterdam UMC]
Tees, M. [Auteur]
Xue, A. [Auteur]
Kite (Gilead)
Shahani, S. [Auteur]
Kite (Gilead)
Nikolajeva, O. [Auteur]
Kite (Gilead)
Kang, J. [Auteur]
Kite (Gilead)
Kaplan, A. [Auteur]
Kite (Gilead)
Schupp, M. [Auteur]
Kite (Gilead)
Miao, H. [Auteur]
Kite (Gilead)
Rich, E. S. [Auteur]
Kite (Gilead)

Titre de la manifestation scientifique :

17th International Conference on Malignant Lymphoma

Ville :

Lugano

Pays :

Suisse

Date de début de la manifestation scientifique :

2023-06-13

Titre de la revue :

Hematological Oncology

Nom court de la revue :

Hematol Oncol

Éditeur :

Wiley

Date de publication :

2023-06-09

ISSN :

1099-1069

Mot(s)-clé(s) en anglais :

aggressive B-cell non-Hodgkin lymphoma
cellular therapies
ongoing trials

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Introduction: The nearly 40% of patients with large B-cell lymphoma (LBCL) who are refractory to or relapse after current first-line standard-of-care (SOC) regimens, such as R-CHOP (rituximab [R] + cyclophosphamide [C], ...
Lire la suite >Introduction: The nearly 40% of patients with large B-cell lymphoma (LBCL) who are refractory to or relapse after current first-line standard-of-care (SOC) regimens, such as R-CHOP (rituximab [R] + cyclophosphamide [C], doxorubicin [H], vincristine [O], and prednisone [P]) and DA-EPOCH-R (dose-adjusted etoposide [DA-E]), have poor prognoses. High International Prognostic Index (IPI) score and the subtype of high-grade B-cell lymphoma (HGBL) are associated with shorter progression-free and overall survival (PFS and OS; Nastoupil LJ and Bartlett NL. J Clin Oncol. 2023). Strategies to improve outcomes in these subgroups have been largely unsuccessful; therefore, therapeutic options with a different mechanism of action are needed. Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved to treat patients with relapsed/refractory LBCL after demonstrating significant clinical benefit as second line (ZUMA-7; Locke FL, et al. N Engl J Med. 2022) and third line and above (ZUMA-1; Neelapu SS, et al. N Engl J Med. 2017) therapy. Additionally, in the Phase 2 ZUMA-12 study in patients with refractory first-line LBCL, axi-cel showed a high rate of durable responses with an objective response rate of 89% (complete response rate, 78%) and an ongoing response rate of 73% (median follow-up, 15.9 months; Neelapu SS, et al. Nat Med. 2022). ZUMA-23 is the first Phase 3, randomized controlled study to evaluate CAR T-cell therapy as a first-line regimen for any cancer and will assess axi-cel versus SOC in patients with high-risk LBCL, defined as IPI 4–5. Methods: The Phase 3 trial design will enroll ≈300 adult patients with high-risk, histologically confirmed LBCL based on the 2016 WHO classification, including diffuse large B-cell lymphoma, HGBL, and transformed follicular or marginal zone lymphoma (Swerdlow SH, et al. Blood. 2016). Eligible patients will receive 1 cycle of R-chemotherapy and then be randomized 1:1 to receive axi-cel or continue with SOC. Patients in the axi-cel arm will undergo leukapheresis and then receive R-CHOP or DA-EPOCH-R as bridging therapy, followed by lymphodepleting chemotherapy (fludarabine/cyclophosphamide), and a single axi-cel infusion (2×106 CAR T cells/kg). Prophylactic corticosteroids may be administered to reduce the incidence and severity of cytokine release syndrome at the investigator’s discretion. Patients in the SOC arm will receive 5 additional cycles of R-CHOP or DA-EPOCH-R (investigator’s choice). The primary endpoint is event-free survival by blinded central review. Key secondary endpoints are OS and PFS. Safety, quality of life, and pharmacokinetics will also be assessed. Patients with a history of HIV and/or hepatitis B or C and undetectable viral loads may enroll. Key exclusion criteria include LBCL of the central nervous system. ZUMA-23 is open for enrollment (NCT05605899).Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
CHU Lille

Collections :

• Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Date de dépôt :

2024-09-06T21:06:59Z
2024-09-26T14:28:54Z
2024-09-26T14:38:51Z